Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cardiac myxomas.

× No keyword cloud information.

4 in total

1. Increased expression and activity of matrix metalloproteinases characterize embolic cardiac myxomas.

Authors: Augusto Orlandi; Alessandro Ciucci; Amedeo Ferlosio; Antonio Pellegrino; Luigi Chiariello; Luigi Giusto Spagnoli
Journal: Am J Pathol Date: 2005-06 Impact factor: 4.307

2. Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3'-deoxy-3'[⁽¹⁸⁾F]-fluorothymidine, [⁽¹⁸⁾F]-FLT imaging and early response evaluation.

Authors: Kalevi Kairemo; Vivek Subbiah
Journal: BMJ Case Rep Date: 2019-05-06

3. Diagnosis and follow up of patients with primary cardiac tumours: a single-centre experience of myxomas.

Authors: S Manduz; N Katrancioglu; O Karahan; O Yucel; M B Yilmaz
Journal: Cardiovasc J Afr Date: 2011 Nov-Dec Impact factor: 1.167

4. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.

Authors: T Erselcan; K J Kairemo; T A Wiklund; M Hernberg; C P Blomqvist; M Tenhunen; J Bergh; H Joensuu
Journal: Br J Cancer Date: 2000-02 Impact factor: 7.640

4 in total

Cardiac myxomas.

1. Increased expression and activity of matrix metalloproteinases characterize embolic cardiac myxomas.

2. Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3'-deoxy-3'[(18)F]-fluorothymidine, [(18)F]-FLT imaging and early response evaluation.

3. Diagnosis and follow up of patients with primary cardiac tumours: a single-centre experience of myxomas.

4. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.

2. Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3'-deoxy-3'[⁽¹⁸⁾F]-fluorothymidine, [⁽¹⁸⁾F]-FLT imaging and early response evaluation.